ADIAL PHARMACEUTICALS, INC.

ADIL Nasdaq CIK: 0001513525

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA, 22901
Mailing Address 1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA, 22901
Phone 434-422-9800
Fiscal Year End 1231
EIN 800667150

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 6, 2026 View on SEC
10-K Annual financial report March 5, 2026 View on SEC
8-K Current report of material events March 3, 2026 View on SEC
8-K Current report of material events February 24, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 18, 2026 View on SEC
8-K Current report of material events February 4, 2026 View on SEC
DEF 14A Definitive proxy statement January 6, 2026 View on SEC
8-K Current report of material events January 6, 2026 View on SEC
424B5 Prospectus supplement December 19, 2025 View on SEC
S-3 Shelf registration for future offerings December 12, 2025 View on SEC

Annual Reports

10-K March 5, 2026
  • Developing AD04 for Alcohol Use Disorder (AUD) in genetically-defined patients, addressing a significant unmet medical need.
  • AD04 utilizes a low-dose version of ondansetron, an active ingredient already approved for other conditions, potentially streamlining development.
View Analysis

Material Events

8-K Other February 24, 2026
High Impact
  • Successfully regained Nasdaq compliance, removing immediate delisting threat.
  • Maintains liquidity and visibility for investors on a major exchange.
View Analysis
8-K Other February 4, 2026
High Impact
  • Preserves Nasdaq listing, which is vital for credibility and visibility.
  • Ensures liquidity and facilitates future funding for clinical trials and operations.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.